January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.
While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...
Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.
4don MSN
Novo Nordisk’s multibillion-dollar honeymoon phase spearheaded by Ozempic and Wegovy is ending. Now the Danish drugmaker is hunting for new patients to maintain its crown as Europe’s most valuable ...
Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, its chief executive said on Wednesday, but it is confident its business is ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo’s record profit from obesity drugs has given the Foundation a war chest to fund its philanthropic grants, although ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback